Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary...

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Interventional Cardiology

Background:

• The DynamX Novolimus-Eluting Coronary Bioadaptor System aims to restore coronary artery function post-treatment by disengaging after polymer resorption.
• This approach contrasts with conventional stenting, which involves permanent vessel caging and potential long-term adverse effects.

Purpose of the Study:

• To evaluate the safety and efficacy of the DynamX Bioadaptor in a first-in-human study.
• To assess long-term clinical outcomes up to 36 months post-implantation.
• To investigate preclinical mechanisms of vessel healing and lumen dynamics.

Main Methods:

• A prospective, multicenter, single-arm study involving 50 patients with de novo coronary lesions.
• Clinical follow-up extended to 36 months, with intention-to-treat analysis.
• Preclinical studies included optical coherence tomography (OCT) and gene expression analysis in pigs.

Main Results:

• At 36 months, target lesion failure was 8.7% (4/46), with no target vessel myocardial infarction or scaffold thrombosis.
• One instance of clinically-driven target lesion revascularization occurred.
• Preclinical OCT showed late lumen enlargement, and gene expression indicated increased contractile genes around 9 months.

Conclusions:

• The DynamX Bioadaptor demonstrated favorable 36-month clinical outcomes, including a lack of device thrombosis and low revascularization rates.
• Preclinical findings support enhanced vessel healing and lumen recovery.
• Larger comparative studies are warranted to evaluate against contemporary drug-eluting stents.